6038-23-9

Basic information

• Product Name: (16E)-3-hydroxy-16-(hydroxyimino)estra-1,3,5(10)-trien-17-one
• Synonyms: 3-Hydroxyestra-1,3,5(10)-triene-16,17-dione 16-oxime
• CAS NO: 6038-23-9
• Molecular Formula: C₁₈H₂₁NO₃
• Molecular Weight: 299.3642
• Mol File: 6038-23-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 514.405°C at 760 mmHg
• Flash Point: 264.903°C
• Density: 1.43g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.704
• CAS DataBase Reference: (16E)-3-hydroxy-16-(hydroxyimino)estra-1,3,5(10)-trien-17-one(CAS DataBase Reference)
• NIST Chemistry Reference: (16E)-3-hydroxy-16-(hydroxyimino)estra-1,3,5(10)-trien-17-one(6038-23-9)
• EPA Substance Registry System: (16E)-3-hydroxy-16-(hydroxyimino)estra-1,3,5(10)-trien-17-one(6038-23-9)

Safety Data

• Hazardous Substances Data: 6038-23-9(Hazardous Substances Data)

Usage

Description

(16E)-3-hydroxy-16-(hydroxyimino)estra-1,3,5(10)-trien-17-one is a synthetic estrogen compound with a chemical structure similar to the natural hormone estrone. It belongs to the class of oximes and has a hydroxy group at position 3 and a hydroxyimino group at position 16. (16E)-3-hydroxy-16-(hydroxyimino)estra-1,3,5(10)-trien-17-one has potential biological activity in regulating hormonal functions, specifically estrogenic activity.

Uses

Used in Medical Research:
(16E)-3-hydroxy-16-(hydroxyimino)estra-1,3,5(10)-trien-17-one is used as a research tool for studying the effects of estrogen on various biological processes and understanding the mechanisms of estrogen action.
Used in Pharmaceutical Development:
(16E)-3-hydroxy-16-(hydroxyimino)estra-1,3,5(10)-trien-17-one is used as a potential therapeutic agent for the treatment of hormonal disorders or conditions related to estrogen imbalance. Its development may lead to new treatments for conditions such as menopause, osteoporosis, and hormone-related cancers.
However, further research is needed to fully understand the pharmacological properties and potential therapeutic uses of (16E)-3-hydroxy-16-(hydroxyimino)estra-1,3,5(10)-trien-17-one.

Upstream product

• 53-16-7 Estrone 
• 865-47-4 potassium tert-butylate 

Relevant articles and documents

Synthesis and investigation of the anticancer effects of estrone-16-oxime ethers in vitro

An expanding body of evidence indicates the possible role of estrane derivatives as useful anticancer agents. The aim of this study was to describe the cytotoxic effects of 63 newly synthetized estrone-16-oxime ethers on human cancer cell lines (cervix carcinoma HeLa, breast carcinoma MCF7 and skin epidermoid carcinoma A431), studied by means of the MTT assay. Four of the most promising compounds were selected for participation in additional experiments in order to characterize the mechanism of action, including cell cycle analysis, morphological study and the 5-bromo-2′-deoxyuridine incorporation assay. The cancer selectivity was tested on a noncancerous fibroblast cell line (MRC-5). Since apoptosis and cell cycle disturbance were observed, caspase-3 activities were further assayed for the two most effective agents. These estrone-16-oxime analogs activated caspase-3 and changed the mRNA level expression of endogenous factors regulating the G1-S phase transition (retinoblastoma protein, CDK4 and p16). The repression of retinoblastoma protein was reinforced at a protein level too. These experimental data lead to the conclusion that estrone-16-oxime ethers may be regarded as potential starting structures for the design of novel anticancer agents.

D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase

A series of novel D-ring modified derivatives of estrone was synthesized and tested as inhibitors of steroid sulfatase (STS). The steroidal D-ring was cleaved via an iodoform reaction and thermal condensation of the resulting marrianolic acid derivative g